|
.....
The Story Behind Dr Nagasawa’s Riboceine Research
During April of 2012, the extraordinary journey behind the
development of Riboceine was revealed to the public…
This is the first time Dr Nagasawa, together with his son Scott Nagasawa
had publicly shared the challenges they faced while remaining dedicated to solving a
serious problem. Although he and his team faced numerous setbacks before this incredible
breakthrough, they never gave up. And it’s the story behind that dedication that we wanted to share
with you today. If you’re not a medical professional, although you might struggle with
understanding the scientific research below, it’s still worth reading. It will give you some
amazing insight into why Dr Nagasawa remained so dedicated to Riboceine research.
How did alcohol abuse play a part in the development of Riboceine?
Dr Nagasawa opened the presentation by talking about the terrible drug and alcohol addictions
veterans were left with, after returning home from the Vietnam War. And how sadly, given the
unpopularity of the War, returning soldiers didn’t receive a warm welcome and were mostly frowned
upon or shunned by society. One of the returning veteran’s who suffered this fate, was Dr
Nagasawa’s own brother.
The popular 80’s movie
Born on the 4th of July gave an excellent
portrayal of the controversy these soldiers faced.  In response to the high percentage of veterans returning home with
debilitating alcohol addictions, the Veteran’s Administration realized they needed
more effective drugs than Antabuse, to prevent alcoholism. They decided they needed new drugs
that could prevent or protect alcoholic’s from developing fatty livers, which leads to
Cirrhosis, eventually a liver transplant, or death.
Dr. Nagasawa then went into detail about how alcohol is metabolized in the body. The challenge he
faced; was it possible to interrupt the metabolizing process of alcohol by trapping acetaldehyde
(AcH) and diverting the product to urinary excretion? Through numerous initial research studies, Dr
Nagasawa’s research team discovered that the MTCA compound, provided
an effective means of delivering cysteine.
Given alcoholics are known to have lower levels of glutathione, they reasoned that using MTCA as a
bioavailable delivery system for cysteine could stimulate the body’s development of glutathione and
protect the liver from the oxidative stress of chronic alcoholism.
“A medical student volunteered to test this theory through a preliminary
experiment”
Because liver damage from consuming alcohol can take a substantial amount of time to
develop, they chose to test on a similar liver problem. An overdose of Acetaminophen, (the active
pain reliever in many over the counter headache/cold and flu medicines), produces liver and kidney
damage similar to the effects of cirrhosis.
The results were very promising, as they showed that L-MTCA could have very similar results to NAC,
the current “gold standard” for treating ACP overdose. From this experiment the team applied for a
grant for further testing. However, a major critique of the grant proposal was that, while MTCA
protects against hepatotoxicity, it also delivers the toxic compound acetaldehyde. Though that
amount was very minuscule, the grant was denied.
Appreciating this denial as part of the rigorous nature of peer review, Dr. Nagasawa knew he had to
keep an open mind while moving forward.
The team knew they needed compounds that were non-toxic to combine with cysteine in order to
effectively deliver it to the cell. They realized that we do have such compounds in our own body,
namely aldose monosaccharide, or the simple sugars produced when glucose is metabolized.
To test this possibility, grad student Jeanette Roberts (Now
Dean of Pharmacology at the university
of Wisconsin) prepared the sugar-cysteine
condensation produced from 8 different aldose saccharides. The next experiment showed that livers
that had an overdose of ACP plus the saccharide D-ribose combined with cysteine had 100% survival
rate from the in vivo experiments, while the next best compound, glucose-cysteine did not perform
nearly as well.
Dr Jannette Roberts video below
Jackpot! Ribose-Cysteine protected the liver from a toxic dose of ACP. Ribose-Cysteine
serves as an effective delivery method of bringing L-cysteine to cells, simulate glutathione
biosynthesis and protecting them from toxins. The ribose-cysteine compound also makes for an ideal
dietary supplement since it’s made from endogenous elements already in our body.
“Dr Nagasawa first published about Riboceine in 1987”
Later experiments also revealed that ribose-cysteine, was even more effective than N-Acetyl
Cysteine in raising glutathione within a liver cell. The presentation concluded withclosing thoughts on Cellgevity. After conducting
numerous experiments, Dr Nagasawa and his research team
know,that thanks to the
technology behind Riboceine, Cellgevity is in a category of it’s own. Riboceine solves the
problem of being able to effectively deliver cysteine to the cell.
Dr Nagasawa’s philosophy in science is, “it’s important to keep an open mind.” His extraordinary
ability to
think outside the box, is what’s enabled him and his research team, to bring Riboceine to the
world.
Dr Nagasawa Bio CV
Dr Herbert Nagasawa was unable to make it to the unveiling of his first Riboceine powered
product as he was being honored by Homeland Security for his groundbreaking cyanide
antidote. It’s a great privilege we have to work alongside such respected and
accomplished scientists at Max. There is a great article detailing the background story
to this breakthrough which you will find a great read to learn more about Herb’s
story.
Midweek Magazine Dr Nagasawa Article
Product Recommendation
None of the information or products in this website are intended to treat, cure or diagnose any
disease. For a medical condition, please consult your Health Professional.
|
